The treatment of renal cell carcinoma (RCC) has changed greatly over the past 15 years.
Progress in the surgical management of the primary tumor and increased understanding of …

Context The role of cytoreductive nephrectomy (CN) in the management of metastatic renal
cell carcinoma (mRCC) in the targeted therapy (TT) era is controversial. Objective To assess …

Antiangiogenic therapy resistance occurs frequently in patients with metastatic renal cell
carcinoma (RCC). The purpose of this study was to understand the mechanism of resistance …

Standard-of-care management of renal cell carcinoma (RCC) indisputably relies on surgery
for low-risk localized tumours and systemic treatment for poor-prognosis metastatic disease …

Cancer-derived small extracellular vesicles (sEVs) induce stromal cells to become
permissive for tumor growth. However, it is unclear whether this induction solely occurs …

Background Previous studies have shown a modest impact of tyrosine kinase inhibitors on
primary renal tumors. Those studies were mostly retrospective or heterogeneous in their …

Purpose Ongoing angiogenesis renders the tumor endothelium unresponsive to
inflammatory cytokines and interferes with adhesion of leukocytes, resulting in escape from …

Purpose The multitargeted tyrosine kinase inhibitor sorafenib is used for the treatment of
advanced-stage renal cell carcinoma. However, the safety and efficacy of this agent have yet …

Purpose: Sarcopenia, a novel concept reflecting the degenerative loss of skeletal muscle
mass, is a critical physiological change during the development of cancer cachexia. We …

Purpose: To investigate the angiogenic changes in primary tumor tissue of renal cell
carcinoma (RCC) patients treated with VEGF-targeted therapy. Experimental Design: Phase …